Clinical Trial Search

Primary: Change in Number of Times Driving After Using Substances — 22.43; 26.50; 26.00 Driving Events

Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL

Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)

Primary: Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757 — 3.81; 4.94; 533; 759 ng/mL

Primary: Renal Oxygenation — 22.4; 22.5 s^-1

Primary: Area Under the Plasma Concentration Time Curve (AUC) From Hour 0 to Infinity (AUC[0-inf]) of Gepotidacin for Part 1 — 14838; 22367; 28545 Nanogram*hour per milliliter

Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min

Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr

Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 1600; 2077; 2210; 2369 Nanogram per milliliter

Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants

Primary: Percent Change in Fractional Excretion of Sodium (FENA) — 41; -5.0 percentage of change — p==0.012

Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Severe Renal Impairment Participants Versus…

Primary: Part 1: Area Under the Plasma Concentration-time Curve of MK-3866 From Time Zero to Infinity (AUC0-inf) — 104; 141; 83.5; 244 µM*hr

Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants

Primary: Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total) — 138169.7; 170105.6 h*ng/mL